Brian Hoh
Chair/Professor | University of Florida
Gainesville, FL, UNITED STATES
Dr. Brian Hoh has expertise in cerebrovascular, endovascular and brain tumor neurosurgery.
Biography
Dr. Brian Hoh is an internationally known expert in the treatment of brain aneurysms, brain arteriovenous malformations, and ischemic and hemorrhagic stroke. He is the chair of the Lillian S. Wells Department of Neurosurgery in the College of Medicine.
Areas of Expertise (6)
Glioblastoma
Intracranial Atherosclerosis
Stroke
Neurosurgery
Brain Aneurysm
Brain Tumors
Articles (3)
Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment
The Lancet NeurologyJose Gutierrez, et al.
2022-03-16
Intracranial atherosclerotic stenosis (ICAS) is one of the most frequent causes of stroke worldwide and confers one of the greatest risks of recurrent stroke compared with other causes of stroke. Asymptomatic ICAS is increasingly recognised as a risk factor for silent brain infarctions and dementia, magnifying the global burden of ICAS.
Severe headache trajectory following aneurysmal subarachnoid hemorrhage: the association with lower sodium levels
Brain InjuryRobert S. Eisinger, et al.
2022-03-30
A clinical hallmark of aneurysmal SAH (aSAH) is headache. Little is known about post-aSAH headache factors which may point to underlying mechanisms. In this study, we aimed to characterize the severity and trajectory of headaches in relation to clinical features of patients with aSAH. This is a retrospective longitudinal study of adult patients admitted to an academic tertiary care center between 2012 and 2019 with aSAH who could verbalize pain scores.
Ticagrelor resistance: a case series and algorithm for management of non-responders
Journal of NeuroInterventional SurgeryDimitri Laurent, et al.
2022-01-18
The placement of cervical and intracranial stents requires the administration of antiplatelet drugs to prevent thromboembolic complications. Ticagrelor has emerged as the most widely used alternative in clopidogrel non-responders owing to its potent antiplatelet effects. Because ticagrelor does not require hepatic activation, many neurointerventionalists choose to forgo laboratory testing of platelet inhibition.
Social